Cargando…

Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non–Small-Cell Lung Cancer Data Set

PURPOSE: Large, generalizable real-world data can enhance traditional clinical trial results. The current study evaluates reliability, clinical relevance, and large-scale feasibility for a previously documented method with which to characterize cancer progression outcomes in advanced non–small-cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Griffith, Sandra D., Miksad, Rebecca A., Calkins, Geoff, You, Paul, Lipitz, Nicole G., Bourla, Ariel B., Williams, Erin, George, Daniel J., Schrag, Deborah, Khozin, Sean, Capra, William B., Taylor, Michael D., Abernethy, Amy P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	Original Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873982/ https://www.ncbi.nlm.nih.gov/pubmed/31403818 http://dx.doi.org/10.1200/CCI.19.00013

Ejemplares similares

Author’s Response to “A Letter in Support of Real-World RECIST”
por: Griffith, Sandra D., et al.
Publicado: (2020)

Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer
por: Griffith, Sandra D., et al.
Publicado: (2019)

An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Non–Small-Cell Lung Cancer
por: Stewart, Mark, et al.
Publicado: (2019)

Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer
por: Khozin, Sean, et al.
Publicado: (2019)

Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality
por: Miksad, Rebecca A., et al.
Publicado: (2017)

Differential frequency in imaging‐based outcome measurement: Bias in real‐world oncology comparative‐effectiveness studies
por: Adamson, Blythe J. S., et al.
Publicado: (2021)

Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types
por: Torres, Aracelis Z., et al.
Publicado: (2022)

Small But Mighty: The Use of Real‐World Evidence to Inform Precision Medicine
por: Miksad, Rebecca A., et al.
Publicado: (2019)

Bridging the divide between clinical research and clinical care in oncology: An integrated real-world evidence generation platform
por: Bourla, Ariel B., et al.
Publicado: (2021)

Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non–Small Cell Lung or Colorectal Cancer
por: Kehl, Kenneth L., et al.
Publicado: (2021)

Development and Validation of a High‐Quality Composite Real‐World Mortality Endpoint
por: Curtis, Melissa D., et al.
Publicado: (2018)

Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma
por: Kubota, Yuta, et al.
Publicado: (2022)

Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin's lymphoma: correlation of complete response, time-to-event and overall survival end points
por: Lee, L., et al.
Publicado: (2011)

Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma
por: Delea, T E, et al.
Publicado: (2012)

Developing and adopting safe and effective digital biomarkers to improve patient outcomes
por: Coravos, Andrea, et al.
Publicado: (2019)

Author Correction: Developing and adopting safe and effective digital biomarkers to improve patient outcomes
por: Coravos, Andrea, et al.
Publicado: (2019)

An evaluation of the impact of missing deaths on overall survival analyses of advanced non–small cell lung cancer patients conducted in an electronic health records database
por: Carrigan, Gillis, et al.
Publicado: (2019)

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer
por: Burzykowski, Tomasz, et al.
Publicado: (2019)

The ends of the world /
por: Danowski, Déborah
Publicado: (2017)

Progression‐free survival at 2 years post‐autologous transplant: a surrogate end point for overall survival in follicular lymphoma
por: Jiménez‐Ubieto, Ana, et al.
Publicado: (2017)

Overall view of Point 5 in Cessy (Oct 2000)
Publicado: (2000)

Geodesics and ends in certain surfaces without conjugate points
por: Eberlein, Patrick B
Publicado: (1978)

Identification of subpopulations that are sensitive to ozone exposure: use of end points currently available and potential use of laboratory-based end points under development.
por: Devlin, R B
Publicado: (1993)

Risk characterization framework for noncancer end points.
por: Pierson, T K, et al.
Publicado: (1991)

Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis
por: Paoletti, Xavier, et al.
Publicado: (2020)

Lactoferrin as a Human Genome “Guardian”—An Overall Point of View
por: Bukowska-Ośko, Iwona, et al.
Publicado: (2022)

Oppositely Charged Nanoparticles Precipitate Not Only at the Point of Overall Electroneutrality
por: Itatani, Masaki, et al.
Publicado: (2023)

End points for biomonitoring: assay sensitivity/selectivity.
por: Aaron, C S, et al.
Publicado: (1996)

The Patient Matters in the End(point)
por: Griffiths, Pip, et al.
Publicado: (2022)

Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record‐Derived Real‐World Data
por: Tan, Katherine, et al.
Publicado: (2021)

Real-world evidence for regulatory decision-making: updated guidance from around the world
por: Burns, Leah, et al.
Publicado: (2023)

Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
por: Abernethy, Amy P., et al.
Publicado: (2017)

Selection of reproductive health end points for environmental risk assessment.
por: Savitz, D A, et al.
Publicado: (1991)

Caregivers' perceived adequacy of support in end-stage lung disease: results of a population survey
por: Currow, David C, et al.
Publicado: (2011)

End-to-End Point Cloud Completion Network with Attention Mechanism
por: Li, Yaqin, et al.
Publicado: (2022)

End-expiratory esophageal pressure versus lower inflection point in acute lung injury
por: Yaroshetskiy, A, et al.
Publicado: (2013)

Observations on the Changing Shape of the Ice Mass and the Determination of the Sublimation End Point in Freeze-Drying: An Application for Through-Vial Impedance Spectroscopy (TVIS)
por: Pandya, Bhaskar, et al.
Publicado: (2021)

Impact of confinement housing on study end-points in the calf model of cryptosporidiosis
por: Graef, Geneva, et al.
Publicado: (2018)

Surveillance Epidemiology and End Results Analysis Demonstrates Improvement in Overall Survival for Cervical Cancer Patients Treated in the Era of Concurrent Chemoradiotherapy
por: Hsu, Howard C., et al.
Publicado: (2015)

Concordance of real-world versus conventional progression-free survival from a phase 3 trial of endocrine therapy as first-line treatment for metastatic breast cancer
por: Huang Bartlett, Cynthia, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uldraphpvfa1t3qnv78tle7c3c